Challenges Loom for FDA Nominee Amid Estrogen Patch Shortages

The nomination of Heidi Overton to lead the U.S. Food and Drug Administration faces significant hurdles, primarily stemming from her longstanding support for President Trump. Senator Bill Cassidy (R-La.), chair of the Health, Education, Labor and Pensions Committee and a proponent of vaccinations, has raised doubts about his support for her confirmation.

Compounding the situation is the rising crisis in the supply of transdermal estrogen patches. Since the FDA revised safety labels for hormone replacement therapy last November, prescriptions have surged, straining production capabilities. The manufacturing process for these patches is complex, resulting in many women having to switch brands and dosages due to limited availability.

Source: www.statnews.com